OR WAIT null SECS
The first results from a trial of a candidate Ebola vaccine at Oxford University suggest the vaccine has an acceptable safety profile at the doses tested, and is able to generate an immune response.
"The vaccine was well tolerated. Its safety profile is pretty much as we had hoped," says professor Adrian Hill of the Jenner Institute at Oxford University, who led the trial.
The researchers say these results suggest the vaccine is suitable for further testing in West Africa during the current outbreak, with the aim of determining whether the vaccine offers protection against Ebola.
The candidate Ebola vaccine is being co-developed by the National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola, which is the one circulating in West Africa. The first doses for use in large scale trials in West Africa have been delivered to Liberia by GSK. The vaccine uses a single Ebola virus gene in a chimpanzee adenovirus to generate an immune response. As it does not contain infectious Ebola virus material, it cannot cause a person who is vaccinated to become infected with Ebola.
The Oxford University trial is one of several safety trials of the GSK/NIH vaccine candidate -- in the U.S., UK, Mali and Switzerland -- that have been fast-tracked in response to the Ebola outbreak in West Africa. The UK trial is funded by the Wellcome Trust, Medical Research Council (MRC) and Department for International Development (DFID). The NIH is providing the NIH/GSK Ebola vaccine for the Oxford University study.
The initial findings were published in the New England Journal of Medicine (NEJM). Sixty healthy volunteers were vaccinated at the University of Oxford's Jenner Institute between Sept. 17 and Nov. 18. The NEJM paper reports safety data and immune responses for the volunteers for 28 days after immunization. Follow-up of the vaccinees will continue beyond these initial data until six months after the volunteers received the experimental vaccine. The volunteers received one of three different vaccine doses. 20 volunteers received a low dose vaccine (1 x 10^10 viral particles (vp)); 20 volunteers a middle dose (2.5 x 10^10 vp); and 20 volunteers a high dose (5 x 10^10 vp). The experimental vaccine was well tolerated at all three doses. The majority of adverse events reported by the volunteers were mild in severity. Two people experienced a moderate fever within 24 hours of receiving the vaccine, but this passed within a day.
"People typically experienced mild symptoms that lasted for one or maybe two days, such as pain or reddening at the injection site, and occasionally people felt feverish," says Hill. 'It's very similar to what has been seen in previous studies with this general type of vaccine."
The primary goal of the trial was to assess safety. However, the scientists also assessed immune responses to Ebola seen in the volunteers before and after vaccination. Importantly, the vaccine generated immune responses against Ebola in the volunteers.
Levels of antibodies increased over a period of 28 days after vaccination, and there was no significant difference in the levels seen at different doses. Levels of T cells -- cellular immunity is the other arm of the body's immune system -- peaked at 14 days.
The levels of antibody response are similar to those seen with a similar vaccine dose in a U.S. study of a related GSK/NIH Ebola vaccine formulation published on Nov 26. They were lower than seen in the U.S. study which tested a significantly higher vaccine dose, but the U.S. study used a formulation not available for control of the ongoing outbreak in West Africa.
The antibody response is lower than antibody levels which were found in macaque monkeys protected by the same vaccine against Ebola. The T cell response, specifically the CD8+ T cell response, was also several fold lower than that observed in protected macaques. However, what level of immune response is needed to protect humans is currently not known. The efficacy of the Ebola vaccine can only be tested in much larger studies in the field during the current outbreak.
"The results are very encouraging in terms of the safety profile of the vaccine. That is the main outcome from this trial," says Hill. "We have seen an immune response in the great majority of people receiving the vaccine. It is possible to be optimistic about the immune responses we've seen; it's also hard to be really confident the levels would be protective. Larger trials in West Africa will be able to tell us more. We are also currently assessing another option, involving a booster dose, for improving immune response levels."
Similar initial results from a U.S. trial in 20 people of a related Ebola vaccine formulation were published on Nov 26. That 'bivalent' GSK/NIH candidate vaccine included a gene for the Zaire species of Ebola, and also a gene for the related Sudan virus.
It is the single, 'monovalent' GSK/NIH candidate vaccine tested at Oxford and other sites which is being taken forward for wider trials in the current Ebola epidemic. Results from trials of the monovalent vaccine in Mali and Switzerland are expected shortly.
The safety and immunogenicity data from the Oxford trial supports the move into much larger scale studies in West Africa, testing vaccine effectiveness to prevent Ebola virus disease.
The Oxford University scientists have also begun testing the safety of a candidate booster vaccine against Ebola, to find out whether it could further increase the immune responses.
Thirty of the original volunteers have been invited back and received a second candidate Ebola vaccine of a different type made by Bavarian Nordic, a company based in Denmark. Ongoing trials in Oxford are still seeking to assess further this two-dose regime. Anyone interested in volunteering should contact firstname.lastname@example.org
Hill says, "The speed at which all this is happening is remarkable. We'd especially like to thank all the volunteers. They continue to take time out of their busy lives to give blood samples at regular intervals so we can understand more about their immune responses having received the vaccine. It's also thanks to the hard work of many scientists, funders, pharma firms, regulators and agencies, all coming together, that we can make such rapid progress. Whether we have a vaccine that is safe, effective and works, we won't know for a while yet. But we owe it to the people who have been affected so badly by the Ebola outbreak to find out.'"
International Development secretary Justine Greening says, "Britain is a world leader in medical research and the outcome of these DFID-funded trials takes us a step closer to finding a vaccine that could help contain Ebola and prevent future outbreaks. I would like to thank the volunteers who took part in this important trial. They join thousands of British doctors, nurses, military personnel, scientists and aid workers in the fight against this terrible disease."
Dr. Jeremy Farrar, director of the Wellcome Trust, says, "This study is very encouraging as it provides good initial evidence that the GSK vaccine will be safe to use in people. However, we still don't know whether it will provide protection against Ebola infection in a real-world situation. That's why trials in West Africa of this, and the other vaccines in development, must begin as soon possible. This has been an amazing global collaboration which we are proud to have supported. Falling infection rates in many of the affected regions increase the urgency of this research. While it is wonderful news that the epidemic is slowing in all three affected countries we cannot consider the crisis over until there are no more people infected by Ebola across the whole region of West Africa. Vaccines may yet play a crucial role in achieving this, and will undoubtedly play a crucial role in protecting against future outbreaks of the virus."
Source: University of Oxford